登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (KYLIN-02)
ClinicalTrials.gov 上登记的一项肝细胞癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06618664,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 9
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(9 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Unresectable locally advanced or metastatic HCC confirmed by histopathologically/cytologically.
入选标准第 3 条
Child-Pugh score of A or B7.
入选标准第 8 条
Patients with liver tumor burden greater than 50% of total liver in volume or received liver transplants.
排除标准第 5 条
ECOG PS of 0-1.
入选标准第 7 条
Active infection, or fever of unknown cause ≥ 38.5℃ in the first 7 days of randomization, or WBC > 15×109/L at baseline.
排除标准第 13 条
At least one measurable lesion based on RECIST v1.1 criteria.
入选标准第 4 条
Patients with other malignancies currently or within the past 5 years.
排除标准第 2 条
Known positive history of human immunodeficiency virus test or acquired immunodeficiency syndrome, known HBV infection, known HCV infection.
排除标准第 14 条
Blood pregnancy negative (women of childbearing age) and non-breastfeeding, effective contraception.
入选标准第 11 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06618664,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Able and willing to provide a written informed consent. ≥ 18 years old, both male and female. Unresectable locally advanced or metastatic HCC confirmed by histopathologically/cytologically. At least one measurable lesion based on RECIST v1.1 criteria. Barcelona clinic liver cancer: Stage B or C. No previous systemic antitumor therapy for HCC. ECOG PS of 0-1. Child-Pugh score of A or B7. Expected survival period ≥ 12 weeks. Adequate organ function. Blood pregnancy negative (women of childbearing age) and non-breastfeeding, effective contraception.排除标准:Exclusion Criteria:
Hepatic cholangiocarcinoma, mixed hepatocellular carcinoma -cholangiocarcinoma, sarcomatoid hepatocellular carcinoma and fibrolamellar hepatocellular carcinoma. Patients with other malignancies currently or within the past 5 years. With known severe allergic reactions to any other monoclonal antibodies. Patients with known CNS metastasis or hepatic encephalopathy. Patients with liver tumor burden greater than 50% of total liver in volume or received liver transplants. Patients with symptomatic ascites or pleural effusion. Patients with hypertension which cannot be well controlled by antihypertensives. Uncontrolled cardiac diseases or symptoms. Known hereditary or acquired bleeding (e.g., coagulopathy) or a tendency to clot (e.g., hemophiliacs). Major vascular disease occurred in the 6 months before randomization. Gastrointestinal perforation or gastrointestinal fistula within 6 months before randomization. Major surgery within 28 days before randomization or expected to require major surgery during the study period. Active infection, or fever of unknown cause ≥ 38.5℃ in the first 7 days of randomization, or WBC > 15×109/L at baseline. Known positive history of human immunodeficiency virus test or acquired immunodeficiency syndrome, known HBV infection, known HCV infection. Patients who received live vaccines within 28 days before randomization, or are expected to be vaccinated during the treatment period Patients with other potential factors that may affect the study results.
引自 ClinicalTrials.gov, NCT06618664, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06618664,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。